Aardvark Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing small-molecule therapies aimed at suppressing hunger and activating innate homeostatic pathways, with lead program ARD-101 in Prader-Willi syndrome and broader metabolic-disease efforts currently under clinical pause/hold review.
What the page says before deeper research
Quality, growth, value, ownership, risk, and source confidence.
Moat 32/100 with high retention risk and low switching costs.
Growth data is unavailable, so this stays mixed until revenue trend data is added.
Valuation is incomplete because P/E or revenue growth is unavailable.
No SEC-backed 13F layer is matched yet, so ownership confirmation is unavailable.
Retention, AI, or valuation against growth could break the thesis.
Fundamentals from Nasdaq quote; Aardvark Q1 2026 10-Q; May 14, 2026 company 8-K/press release; Stock Analysis summary/statistics as of 2026-05-21; ownership confirmation is not available here.
Next earnings date: Unavailable
Beginner valuation check
Data pending from FMP or Finnhub.
Unavailable from cited sources.
Unavailable from cited sources.
Trailing P/E is negative because the company is loss-making; quote source showed about -1.43.
Source: market data index. As of May 21, 2026. P/E can be unavailable or misleading when earnings are negative.
Beginner guide
Aardvark is a drug company working on a pill that may help people feel less extreme hunger.
It develops small-molecule medicines that activate gut and body signaling pathways tied to hunger and metabolism. Its lead drug, ARD-101, has been studied for hyperphagia in Prader-Willi syndrome, while other programs target obesity-related uses and a newer dermatology pipeline.
Right now it does not make product revenue. If its drugs succeed, it could make money from approved drug sales, licensing deals, or partnerships.
The company targets a serious unmet need in PWS and a much larger obesity opportunity. Because it is small and pre-revenue, one regulatory update can move the stock a lot.
Clinical trials can fail, the FDA clinical hold on ARD-101 may last longer than hoped, cash can run down before approval, and newer side programs may not offset problems in the lead asset.
Think of Aardvark like a startup building a special dimmer switch for the body's hunger alarm. If the switch works safely, it could be valuable; if it does not, the whole project loses value fast.
This is a high-risk biotech whose story is still mostly about one lead program and whether management can resolve current regulatory issues.
Aardvark's lead oral small-molecule drug candidate for reducing hunger signals, especially in PWS.
Prader-Willi syndrome, a rare genetic disorder that can cause extreme, relentless hunger.
Aardvark's Phase 3 pivotal study of ARD-101 in people with PWS.
An FDA action that pauses study activity until the agency's concerns are addressed.
A planned fixed-dose combination program tied to obesity and metabolic disease.
Aardvark's wholly owned subsidiary created to advance its dermatology pipeline, including DIA-615.
The first four questions
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Bull / Neutral / Bear
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Unavailable from cited sources.
Beginner checklist
Next earnings date: Unavailable
Revenue growth: No product revenue to date
Margin trend: Not meaningful yet for a pre-revenue biotech
Forward P/E: Unavailable
13F ownership changes: Watch after future SEC-backed filings populate
Insider buying/selling: Monitor Form 4 activity
Main company-specific KPI: ARD-101 clinical hold resolution and restart path
Aardvark Therapeutics, Inc. is exposure to healthcare operating model with low switching costs and 100% net revenue retention.
Moat is mostly IP, know-how, and orphan-disease positioning around hunger biology rather than scale or distribution.
Retention risk is elevated, so the durability of recurring demand matters more than the headline market size.
Pro access unlocks the workflow simulator for this company brief.
Simulator coverage pending
This ticker has a company brief, but richer workflow modules have not been built yet.
No SEC-backed 13F rows are matched for this ticker yet. We do not fabricate ownership rows.
- Moat is mostly IP, know-how, and orphan-disease positioning around hunger biology rather than scale or distribution.
- ARD-101's PWS focus and rare-disease designations could create niche defensibility if approved, but that edge is still unproven.
- The full FDA clinical hold sharply weakens moat durability because the company remains highly dependent on one lead asset.
- A new dermatology subsidiary broadens optionality, yet it is too early to count as a strong competitive barrier.